MINI REVIEW
Year : 2014  |  Volume : 5  |  Issue : 1  |  Page : 12-14

The new factor Xa inhibitor: Apixaban


Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India

Correspondence Address:
Sangeeta Bhanwra
Department of Pharmacology, Government Medical College and Hospital, House No. 1152, Sector 32 B, Chandigarh 160 030
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-500X.124409

Rights and Permissions

Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like unpredictable pharmacokinetic profile, parenteral route (with heparin and its derivatives only), narrow therapeutic window, and constant laboratory monitoring for their efficacy and safety. This lead to the development of novel factor Xa inhibitors which could be given orally, have predictable dose response relationship and are associated with lesser hemorrhagic complications. They include rivaroxaban, apixaban, and edoxaban among others. Apixaban has currently been approved for use in patients undergoing total knee or hip replacement surgery and to prevent stroke in patients with atrial fibrillation. Many trials are ongoing for apixaban to firmly establish its place in future, among the anti-thrombotic drugs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3400    
    Printed73    
    Emailed1    
    PDF Downloaded1128    
    Comments [Add]    
    Cited by others 6    

Recommend this journal